Managing blood side effects from breast cancer targeted drugs
Part of Cancer, Skin clinical trials.
This study looks at how well current methods manage low blood cell counts (low platelets, low white blood cells, and low red blood cells) that can happen from targeted therapies for breast cancer. If you have breast cancer and are getting or have gotten a targeted therapy, this trial could help improve care for side effects like these.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have any type of breast cancer.
- You are currently receiving or have completed targeted therapy (a type of treatment that targets specific cancer cells).
- Your doctor thinks you need treatment or prevention for low platelets, low white blood cells, or low red blood cells caused by targeted therapy.
- You are not pregnant or breastfeeding.
- You can understand the study and give your consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
This trial tests a new version of a drug called romiplostim to help raise platelet counts in breast cancer patients whose platelets drop because of chemotherapy. Raising your platelets may reduce the risk of bleeding and allow you to continue your cancer treatment.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This study uses special cells grown in a lab to understand why some cancer treatments cause side effects. It may help researchers find ways to predict and prevent these side effects in the future.
This study tests whether a different way of giving standard chemoradiation can lower the risk of blood-related side effects (like low blood cell counts) in people with locally advanced cervical cancer, while still controlling the disease.
This trial tests a new combination of two medicines (hetrombopag and rhTPO) that help raise platelet counts, which often drop during cancer treatment. The goal is to see if this approach works well and is safe for people with low platelets caused by cancer therapy.
Hear when a new Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.